Redeye: Saniona - A new chapter for tesofensine
Saniona’s partner Medix has initiated a Phase 3 trial for tesofensine in patients with obesity. This study is intended to form the basis for market approval in Mexico. The trial has got off to a flying start and after only a month, 40 percent of the total number of patients have been recruited.
Read more and download the Research Update: https://goo.gl/Rcg9Cy
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/